PSYENCE BIOMEDICAL LTD (PBM) Stock Price, Quote, News and Summary
NASDAQ:PBM - Nasdaq - CA74449F1009 - Common Stock
PBM Quote and Key Statistics
PSYENCE BIOMEDICAL LTD
NASDAQ:PBM (1/21/2025, 8:19:31 PM)
After market: 1.71 -0.01 (-0.58%)1.72
-0.07 (-3.91%)
PBM Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PBM Performance and Technical Analysis
PBM Ownership and Analysts
PBM Latest News and Analysis
Psyence Biomed Announces Closing of $2.0 Million Private Placement
NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has closed...
Psyence Biomed Announces $2.0 Million Private Placement
NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company“) today announced that it has entered...
Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements
Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheet...
Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial
Patient screening underway; first patient expected to be randomized into the study in January A leading clinical trial site management organization (SMO),...
About PBM
Company Profile
Psyence Biomedical Ltd. is a life science biotechnology company. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-12-10. The firm has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.
Company Info
PSYENCE BIOMEDICAL LTD
121 Richmond Street West Penthouse, Suite 1300
TORONTO ONTARIO V6E 3Z3 CA
CEO: John Plourde
Employees: 0
Company Website: http://psyence.com
Investor Relations: http://psyence.com/investors/
Phone: 17744604171
PBM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.06 | 305.03B | ||
| AMGN | AMGEN INC | 14.3 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839 | 110.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.14 | 75.58B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.28B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.63 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 16.43B |